Bone Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: BNC003 MIFTS: 58	Bone Cancer Categories: Bone diseases, Cancer diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Bone Cancer

MalaCards integrated aliases for Bone Cancer:

Name: Bone Cancer ¹² ⁴³ ¹⁵

Bone Carcinoma ¹² ¹⁵ ⁷³

Malignant Bone Neoplasm ¹² ⁷³

Bone Neoplasms ⁴⁴ ⁷³

Malignant Neoplasm of Bone ¹²

Malignant Osseous Tumor ¹²

Malignant Bone Tumour ¹²

Osteosarcoma of Bone ⁷³

Osteogenic Neoplasm ⁷³

Ca - Bone Cancer ¹²

Neoplasm of Bone ¹²

Bone Neoplasm ¹²

Osseous Tumor ¹²

Bone Tumour ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Bone diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:184 DOID:2762

MeSH ⁴⁴ D001859

NCIt ⁵⁰ C9343 C36082

UMLS ⁷³ C0005967 C0700110 C0279530 more

Sources

Summaries for Bone Cancer

MedlinePlus : ⁴³ Cancer that starts in a bone is uncommon. Cancer that has spread to the bone from another part of the body is more common. There are three types of bone cancer: Osteosarcoma - occurs most often between ages 10 and 19. It is more common in the knee and upper arm. Chondrosarcoma - starts in cartilage, usually after age 40 Ewing's sarcoma - occurs most often in children and teens under 19. It is more common in boys than girls. The most common symptom of bone cancer is pain. Other symptoms vary, depending on the location and size of the cancer. Surgery is often the main treatment for bone cancer. Other treatments may include amputation, chemotherapy, and radiation therapy. Because bone cancer can come back after treatment, regular follow-up visits are important. NIH: National Cancer Institute

MalaCards based summary : Bone Cancer, also known as bone carcinoma, is related to ewing sarcoma and villonodular synovitis, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Bone Cancer is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are TNFR1 Pathway and Development Endothelin-1/EDNRA signaling. The drugs Quadramet and Xgeva have been mentioned in the context of this disorder. Affiliated tissues include bone, spinal cord and dorsal root ganglion, and related phenotypes are behavior/neurological and growth/size/body region

Disease Ontology : ¹² A bone cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

Sources

Related Diseases for Bone Cancer

Diseases in the Bone Cancer family:

Bone Benign Neoplasm

Primary Bone Cancer

Diseases related to Bone Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 145)

#	Related Disease	Score	Top Affiliating Genes
1	ewing sarcoma	31.5	BMI1 CYCS EWSR1 IL6 MMP9
2	villonodular synovitis	29.8	MMP9 TNFSF11
3	giant cell tumor	29.6	MMP9 TNFRSF11A TNFSF11
4	bone disease	29.5	COL1A1 IL6 TNFRSF11A TNFSF11
5	bone resorption disease	29.3	COL1A1 ESR1 IL6 TNFRSF11A TNFSF11 TRPV1
6	osteoporosis	29.2	CNR1 COL1A1 ESR1 IL6 TNFRSF11A TNFSF11
7	chest wall bone cancer	12.2
8	primary bone cancer	12.1
9	bone marrow cancer	11.3
10	maxillary cancer	11.0
11	adamantinoma of long bones	10.9
12	osteogenic sarcoma	10.9
13	aneurysmal bone cysts	10.9
14	bone squamous cell carcinoma	10.8
15	chondrosarcoma	10.8
16	multiple enchondromatosis, maffucci type	10.8
17	bone fracture	10.8
18	long bones of lower limb cancer	10.8
19	jaw cancer	10.8
20	orbital cancer	10.8
21	bone giant cell tumor	10.8
22	sternum cancer	10.8
23	paget's disease of bone	10.8
24	femoral cancer	10.8
25	bone lymphoma	10.8
26	osteoblastoma	10.4
27	polyarticular onset juvenile idiopathic arthritis	10.3	TNFRSF11A TNFSF11
28	breast leiomyosarcoma	10.3	TNFRSF11A TNFSF11
29	pain agnosia	10.3	CNR1 PDYN TRPV1
30	hemophilic arthropathy	10.3	TNFRSF11A TNFSF11
31	agnosia	10.3	CNR1 PDYN TRPV1
32	cyclic vomiting syndrome	10.3	CNR1 IL6
33	osteopetrosis, autosomal recessive 7	10.3	TNFRSF11A TNFSF11
34	specific developmental disorder	10.3	CNR1 PDYN TRPV1
35	paget disease of bone 5, juvenile-onset	10.3	TNFRSF11A TNFSF11
36	periapical periodontitis	10.2	IL6 TNFRSF11A TNFSF11
37	root resorption	10.2	P2RX7 TNFRSF11A TNFSF11
38	oslam syndrome	10.2
39	malignant neoplasm of short bones of lower limb	10.2
40	mandibular cancer	10.2
41	ameloblastic carcinoma	10.2
42	periodontitis, chronic	10.2	IL6 TNFSF11
43	disease of mental health	10.2	CNR1 PDYN TRPV1
44	drug dependence	10.2	CNR1 PDYN PENK
45	osteoporotic fracture	10.2	COL1A1 ESR1 IL6
46	autoimmune disease of central nervous system	10.2	CCL2 IL6 TRPV1
47	mouth disease	10.2	IL6 TNFSF11 TRPV1
48	autoimmune disease of the nervous system	10.2	CCL2 IL6 TRPV1
49	adenomyosis	10.2	ESR1 MMP9 TRPV1
50	cystitis	10.2	CCL2 IL6 TRPV1

Graphical network of the top 20 diseases related to Bone Cancer:

Sources

Symptoms & Phenotypes for Bone Cancer

UMLS symptoms related to Bone Cancer:

back pain, sciatica, muscle cramp

MGI Mouse Phenotypes related to Bone Cancer:

⁴⁶ (show all 14)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	10.34	ATF3 CNR1 COL1A1 CYCS ESR1 IL6
2	growth/size/body region	MP:0005378	10.29	ATF3 CNR1 COL1A1 CYCS ESR1 IL6
3	immune system	MP:0005387	10.22	ATF3 CCL2 COL1A1 CYCS ESR1 IL6
4	homeostasis/metabolism	MP:0005376	10.21	ATF3 CNR1 COL1A1 ESR1 IL6 MMP9
5	cardiovascular system	MP:0005385	10.16	COL1A1 CYCS ESR1 IL6 MMP9 MTAP
6	hematopoietic system	MP:0005397	10.16	ATF3 COL1A1 CYCS ESR1 IL6 MMP9
7	integument	MP:0010771	10.15	ATF3 CNR1 COL1A1 ESR1 IL6 MMP9
8	adipose tissue	MP:0005375	10.08	ATF3 CNR1 COL1A1 ESR1 IL6 PDYN
9	digestive/alimentary	MP:0005381	10.04	CNR1 COL1A1 ESR1 IL6 MMP9 PDYN
10	limbs/digits/tail	MP:0005371	9.87	COL1A1 ESR1 MMP9 P2RX7 PENK TNFRSF11A
11	neoplasm	MP:0002006	9.86	ATF3 COL1A1 ESR1 IL6 MMP9 TNFRSF11A
12	no phenotypic analysis	MP:0003012	9.81	ATF3 CNR1 COL1A1 ESR1 PDYN PENK
13	respiratory system	MP:0005388	9.56	ATF3 COL1A1 ESR1 IL6 MMP9 MTAP
14	skeleton	MP:0005390	9.36	CNR1 COL1A1 CYCS ESR1 IL6 MMP9

Sources

Drugs & Therapeutics for Bone Cancer

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Quadramet ¹⁸	SAMARIUM SM-153 LEXIDRONAM PENTASODIUM	DuPont Merck Pharmaceutical Company	March 1997
FDA Label: Quadramet Disease/s that Drug Treats:pain associated with bone cancer Indications and Usage: ¹⁸ DrugBank Targets: - Mechanism of Action: ¹⁸ Target: osteoblastic tumor sites Action: irradiator FDA: -
2	Xgeva ¹⁸ ⁴⁹	DENOSUMAB	Amgen	June 2013/ November 2010
FDA Label: Xgeva Disease/s that Drug Treats:giant cell tumor of bone/ prevention of skeletal-related events in patients with bone metastases from solid tumors Indications and Usage: ¹⁸ Xgeva is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with bone metastasesfrom solid tumors (1.1) Treatment of adults and skeletally mature adolescents with giant celltumor of bone that is unresectable or where surgical resection is likely toresult in severe morbidity (1.2, 14.2) Treatment of hypercalcemia of malignancy refractory to bisphosphonatetherapy (1.3)Limitation of use: Xgeva is not indicated for the prevention of skeletal-relatedevents in patients with multiple myeloma DrugBank Targets: ¹⁶ 1. Tumor necrosis factor ligand superfamily member 11 Mechanism of Action: ¹⁸ Target: RANKL Action: modulator of calcium release FDA: Xgeva binds to RANKL, a transmembrane or soluble protein essential for the formation, function, andsurvival of osteoclasts, the cells responsible for bone resorption, thereby modulating calcium release frombone. Increased osteoclast activity, stimulated by RANKL, is a mediator of bone pathology in solidtumors with osseous metastases. Similarly, giant cell tumors of bone consist of stromal cells expressingRANKL and osteoclast-like giant cells expressing RANK receptor, and signaling through the RANKreceptor contributes to osteolysis and tumor growth. Xgeva prevents RANKL from activating itsreceptor, RANK, on the surface of osteoclasts, their precursors, and osteoclast-like giant cells.
3	Xofigo ¹⁸ ⁴⁹	RADIUM RA-223 DICHLORIDE	Bayer Healthcare Pharmaceuticals	May 2013
FDA Label: Xofigo Disease/s that Drug Treats:prostate cancer with bone metastases Indications and Usage: ¹⁸ Xofigo is an alpha particle-emitting radioactive therapeutic agent indicated forthe treatment of patients with castration-resistant prostate cancer, symptomaticbone metastases and no known visceral metastatic disease. (1) DrugBank Targets: - Mechanism of Action: ¹⁸ Target: bone mineral hydroxyapatite at areas of increased bone turnover Action: forms complexes, destroys DNA FDA: The active moiety of Xofigo is the alpha particle-emitting isotope radium-223 (as radium Ra 223 dichloride), whichmimics calcium and forms complexes with the bone mineral hydroxyapatite at areas of increased bone turnover, such asbone metastases (see Table 2). The high linear energy transfer of alpha emitters (80 keV/micrometer) leads to a highfrequency of double-strand DNA breaks in adjacent cells, resulting in an anti-tumor effect on bone metastases. The alphaparticle range from radium-223 dichloride is less than 100 micrometers (less than 10 cell diameters) which limits damageto the surrounding normal tissue.
4	Zometa ¹⁸ ⁴⁹	ZOLEDRONIC ACID	Novartis	August 2001/ February 2002
FDA Label: Zometa Disease/s that Drug Treats:Hypercalcemia of malignancy/ Multiple myeloma; bone metastases from solid tumors Indications and Usage: ¹⁸ Zometa is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy. (1.1) Patients with multiple myeloma and patients with documented bonemetastases from solid tumors, in conjunction with standard antineoplastictherapy. Prostate cancer should have progressed after treatment with atleast one hormonal therapy. (1.2)Important limitation of use: The safety and efficacy of Zometa has not beenestablished for use in hyperparathyroidism or nontumor-relatedhypercalcemia. (1.3) DrugBank Targets: ¹⁶ 1. Farnesyl pyrophosphate synthase;2. Geranylgeranyl pyrophosphate synthase;3. Hydroxylapatite Mechanism of Action: ¹⁸ Target: bone resorption Action: inhibitor FDA: The principal pharmacologic action of zoledronic acid is inhibition of bone resorption. Although theantiresorptive mechanism is not completely understood, several factors are thought to contribute to this action.In vitro, zoledronic acid inhibits osteoclastic activity and induces osteoclast apoptosis. Zoledronic acid alsoblocks the osteoclastic resorption of mineralized bone and cartilage through its binding to bone. Zoledronic acidinhibits the increased osteoclastic activity and skeletal calcium release induced by various stimulatory factorsreleased by tumors.

Drugs for Bone Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 463)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Hydrocortisone acetate

Approved, Vet_approved

Phase 4

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 4

50-23-7

5754

Prednisone

Approved, Vet_approved

Phase 4,Phase 2,Phase 1

53-03-2

5865

Zoledronic acid

Approved

Phase 4,Phase 2,Phase 3,Phase 1

118072-93-8

68740

Denosumab

Approved

Phase 4,Phase 3,Phase 2,Phase 1

615258-40-7

Dopamine

Approved

Phase 4,Phase 2

51-61-6, 62-31-7

681

Methamphetamine

Approved, Illicit

Phase 4

537-46-2

10836

Radium Ra 223 dichloride

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2

444811-40-9

Lithium carbonate

Approved

Phase 4

554-13-2

Heparin

Approved, Investigational

Phase 4,Not Applicable

9005-49-6

772 46507594

Dalteparin

Approved

Phase 4,Not Applicable

9005-49-6

Enoxaparin

Approved

Phase 4

9005-49-6

772

Aspirin

Approved, Vet_approved

Phase 4

50-78-2

2244

Pregabalin

Approved, Illicit, Investigational

Phase 4

148553-50-8

5486971

Vitamin D

Approved, Nutraceutical, Vet_approved

Phase 4,Phase 2,Phase 1

1406-16-2

Hormones

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Anti-Inflammatory Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Hydrocortisone 17-butyrate 21-propionate

Phase 4

glucocorticoids

Phase 4,Phase 3,Phase 2,Phase 1

Hydrocortisone-17-butyrate

Phase 4

Hormone Antagonists

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Anesthetics

Phase 4,Phase 3,Phase 1,Not Applicable

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Antineoplastic Agents, Hormonal

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Cortisol succinate

Phase 4

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Diphosphonates

Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Bone Density Conservation Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Calcium, Dietary

Phase 4,Phase 1,Phase 2,Not Applicable

Vitamins

Phase 4,Phase 2,Phase 1,Not Applicable

Immunologic Factors

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Analgesics

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Analgesics, Non-Narcotic

Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable

Anti-Inflammatory Agents, Non-Steroidal

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Antirheumatic Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Adrenergic Agents

Phase 4,Not Applicable

Neurotransmitter Uptake Inhibitors

Phase 4

Sympathomimetics

Phase 4

Dopamine Uptake Inhibitors

Phase 4

Central Nervous System Stimulants

Phase 4,Phase 3,Phase 2,Phase 1

Dopamine Agents

Phase 4,Phase 2

Neurotransmitter Agents

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Autonomic Agents

Phase 4,Phase 3,Phase 2,Phase 1

Ibandronic acid

Phase 4,Phase 3,Phase 2

Calciferol

Phase 4,Phase 2,Phase 1

Central Nervous System Depressants

Phase 4,Phase 3,Phase 1,Early Phase 1,Not Applicable

Antibodies

Phase 4,Phase 3,Phase 2,Phase 1

Immunoglobulins

Phase 4,Phase 3,Phase 2,Phase 1

Antibodies, Monoclonal

Phase 4,Phase 3,Phase 2,Phase 1

Cyclooxygenase Inhibitors

Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 769)

#	Name	Status	NCT ID	Phase	Drugs
1	The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy	Unknown status	NCT02905916	Phase 4	PEG-rhG-CSF
2	Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions	Unknown status	NCT02190994	Phase 4	Hydrocortisone;Prednisone
3	Bioactive Glass Granules in Filling of Bone Defects	Completed	NCT01304121	Phase 4
4	Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases	Completed	NCT00434447	Phase 4	Zoledronic acid
5	A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer	Completed	NCT02553707	Phase 4	Ibandronate
6	A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease	Completed	NCT02564107	Phase 4	Ibandronate
7	FREE Study - Fracture Reduction Evaluation	Completed	NCT00211211	Phase 4
8	Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients	Completed	NCT01129336	Phase 4	Zoledronic acid;Standard Therapy
9	Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates	Completed	NCT00765687	Phase 4	bisphosphates
10	Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis	Completed	NCT00762346	Phase 4	zometa
11	Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis	Completed	NCT00241111	Phase 4	zoledronic acid
12	Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis	Completed	NCT00237159	Phase 4	Zoledronic acid
13	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer	Completed	NCT00334139	Phase 4	Zoledronic Acid
14	Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma	Recruiting	NCT01669369	Phase 4	Lithium Carbonate;Placebo
15	Radium-223 Dichloride Long-term Follow-up Program	Recruiting	NCT02312960	Phase 4
16	Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004	Active, not recruiting	NCT03301857	Phase 4	Denosumab (Cohort A)
17	Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology	Enrolling by invitation	NCT03244020	Phase 4	Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
18	Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer	Not yet recruiting	NCT02480634	Phase 4	Zoledronic acid
19	A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer	Terminated	NCT00381095	Phase 4	Pregabalin;Placebo
20	Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma	Unknown status	NCT00691236	Phase 2, Phase 3	Zoledronic acid;Standard chemotherapy
21	A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma	Unknown status	NCT02099396	Phase 2, Phase 3	Docetaxel+lobaplatin;Gemcitabine+lobaplatin
22	Laser Therapy Prevents Mucositis Oral in Chemotherapy for Bone Marrow Transplantation?	Unknown status	NCT02020928	Phase 3
23	Non-invasive Focal Therapy for Osteoid Osteoma	Unknown status	NCT02302651	Phase 2, Phase 3
24	Biological Image Guided Antalgic Stereotactic Body Radiotherapy of Bone Metastases	Unknown status	NCT01429493	Phase 2, Phase 3
25	F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets	Unknown status	NCT00882609	Phase 3
26	Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma	Unknown status	NCT00002516	Phase 3	cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
27	Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma	Unknown status	NCT00020566	Phase 3	busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
28	Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care Involvement	Unknown status	NCT01813240	Phase 2, Phase 3	Minocycline;placebo
29	SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors	Unknown status	NCT00517959	Phase 3
30	Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy	Completed	NCT02711007	Phase 2, Phase 3	apatinib
31	Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in Osteosarcoma Children	Completed	NCT00180908	Phase 3	Etoposide, Ifosfamide, Methotrexate;Doxorubicin, Methotrexate
32	Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma	Completed	NCT01176981	Phase 3	High Dose Methotrexate
33	Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study	Completed	NCT00001217	Phase 3	pre-surgical chemotherapy
34	Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma	Completed	NCT00002539	Phase 3	cisplatin;doxorubicin hydrochloride
35	Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma	Completed	NCT00003937	Phase 3	cisplatin;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;methotrexate
36	Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy	Completed	NCT00716976	Phase 3	sodium thiosulfate
37	A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer	Completed	NCT02716792	Phase 3	Ibandronate
38	A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease	Completed	NCT02561039	Phase 3	Ibandronate
39	Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy	Completed	NCT00041665	Phase 3	Recombinant Human Keratinocyte Growth Factor
40	Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)	Completed	NCT00538239	Phase 3	ridaforolimus;Placebo
41	Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma	Completed	NCT00346164	Phase 3	doxorubicin hydrochloride;ifosfamide
42	Dexamethasone for Pain Flare After Radiotherapy of Painful Bone metastasesZonMW 11510009	Completed	NCT01669499	Phase 3	Dexamethasone acetate;Placebo
43	Palliation: the Effect of Education on Pain	Completed	NCT01358539	Phase 3
44	Dexamethasone vs Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases	Completed	NCT01248585	Phase 3	Dexamethasone;Placebo
45	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
46	Evaluation of Vertebroplasty Associated With Radiotherapy for Spine Metastases (EVAR)	Completed	NCT00267033	Phase 3
47	Palliative Radiotherapy for Bone Metastases: Single Versus Multiple Fractions.	Completed	NCT00858741	Phase 3
48	Optimization of Radiotherapy in Treatment of Painful Bone Metastasis	Completed	NCT00610272	Phase 3
49	Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma	Completed	NCT00219258	Phase 3	Zoledronic acid
50	Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant	Completed	NCT00305851	Phase 3

Search NIH Clinical Center for Bone Cancer

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :

zoledronic

zoledronic acid

Cochrane evidence based reviews: bone neoplasms

Sources

Genetic Tests for Bone Cancer

Sources

Anatomical Context for Bone Cancer

MalaCards organs/tissues related to Bone Cancer:

⁴¹

Bone, Spinal Cord, Dorsal Root Ganglion, Lung, Prostate, Liver, Thyroid

Sources

Publications for Bone Cancer

Articles related to Bone Cancer:

(show top 50) (show all 493)

#	Title	Authors	Year
1	Suppression of HDAC2 in Spinal Cord Alleviates Mechanical Hyperalgesia and Restores KCC2 Expression in a Rat Model of Bone Cancer Pain. ( 29482000 )	Hou X....Guo Q.	2018
2	Adverse events associated with aprepitant pediatric bone cancer patients. ( 29409391 )	Okumura L.M....Moreira L.B.	2018
3	A Kappa Opioid Receptor Agonist Blocks Bone Cancer Pain Without Altering Bone Loss, Tumor Size, or Cancer Cell Proliferation in a Mouse Model of Cancer-Induced Bone Pain. ( 29371114 )	Edwards K.A....Streicher J.M.	2018
4	Socio-economic patterning in early mortality of patients aged 0-49 years diagnosed with primary bone cancer in Great Britain, 1985-2008. ( 29414632 )	Blakey K....McNally R.J.Q.	2018
5	IL-18 Contributes to Bone Cancer Pain by Regulating Glia Cells and Neuron Interaction. ( 29079540 )	Liu S....Liu G.J.	2018
6	Longitudinal resting-state fMRI in a mouse model of metastatic bone cancer reveals distinct functional reorganizations along a developing chronic pain state. ( 29319607 )	Buehlmann D....Rudin M.	2018
7	Expression of BDNF in dorsal root ganglion of rats with bone cancer pain and its effect on pain behavior. ( 29504577 )	Huang Y.	2018
8	Inhibition of Connexin 43 and Phosphorylated NR2B in Spinal Astrocytes Attenuates Bone Cancer Pain in Mice. ( 29867362 )	Yang H....Wu L.	2018
9	Spinal PKC activation - Induced neuronal HMGB1 translocation contributes to hyperalgesia in a bone cancer pain model in rats. ( 29428215 )	An K....Yao M.	2018
10	CORR InsightsAr: Can Augmented Reality Be Helpful in Pelvic Bone Cancer Surgery? An In Vitro Study. ( 29762155 )	Gerrand C.	2018
11	Lectin-conjugated pH-responsive mesoporous silica nanoparticles for targeted bone cancer treatment. ( 29127069 )	MartA-nez-Carmona M....Vallet-RegA- M.	2018
12	Hedgehog signaling contributes to bone cancer pain by regulating sensory neuron excitability in rats. ( 29607715 )		2018
13	Activation of ventral tegmental area dopaminergic neurons reverses pathological allodynia resulting from nerve injury or bone cancer. ( 29357732 )		2018
14	Electrical peripheral nerve stimulation relieves bone cancer pain by inducing Arc protein expression in the spinal cord dorsal horn. ( 29606887 )		2018
15	Neuronal complement cascade drives bone cancer pain via C3R mediated microglial activation. ( 29909203 )		2018
16	Dehydrocorydaline attenuates bone cancer pain by shifting microglial M1/M2 polarization toward the M2 phenotype. ( 29882480 )		2018
17	<sup>18</sup>F-Fluoride PET/CT and <sup>99m</sup>Tc-MDP SPECT/CT can detect bone cancer at early stage in rodents. ( 29778807 )		2018
18	Preconditioning with hydrogen sulfide prevents bone cancer pain in rats through a proliferator-activated receptor gamma/p38/Jun N-terminal kinase pathway. ( 29096563 )		2018
19	Blockage of spinal endothelin A receptors attenuates bone cancer pain via regulation of the Akt/ERK signaling pathway in mice. ( 29395120 )		2018
20	Health professional perceptions of communicating with adolescents and young adults about bone cancer clinical trial participation. ( 29978324 )		2018
21	A new method for selecting auricle positions in skull base reconstruction for temporal bone cancer. ( 29574745 )		2018
22	Fluoridation and county-level secondary bone cancer among cancer patients 18 years or older in New York State. ( 30109528 )	Crnosija N...Meliker JR	2018
23	Activation of the P2X7 receptor in midbrain periaqueductal gray participates in the analgesic effect of tramadol in bone cancer pain rats. ( 30198382 )	Li P...Qin Y	2018
24	Bone Cancer: Diagnosis and Treatment Principles. ( 30215968 )	Ferguson JL...Turner SP	2018
25	Bone Cancer. ( 30215985 )		2018
26	Bone morphogenetic protein and activin membrane-bound inhibitor suppress bone cancer progression in MG63 and SAOS cells via regulation of the TGF-β-induced EMT signaling pathway. ( 30250579 )	Liu F...Yang YL	2018
27	In vitro evaluation of a biomaterial-based anticancer drug delivery system as an alternative to conventional post-surgery bone cancer treatment. ( 30274043 )	Bischoff I...Unger RE	2018
28	Iodine-125 seed implantation combined with arterial chemoembolization therapy for pain palliation in metastatic bone cancer: a retrospective study. ( 30296196 )	Yang Z...Jin L	2018
29	Bone-Cancer Assessment and Destruction Pattern Analysis in Long-Bone X-ray Image. ( 30367308 )	Bandyopadhyay O...Bhattacharya BB	2018
30	Decitabine attenuates nociceptive behavior in a murine model of bone cancer pain. ( 30422869 )	Appel CK...Heegaard AM	2018
31	Upregulation of Spinal Voltage-Dependent Anion Channel 1 Contributes to Bone Cancer Pain Hypersensitivity in Rats. ( 29196874 )	Kong X....Jiang G.Q.	2017
32	STAT1 as a downstream mediator of ERK signaling contributes to bone cancer pain by regulating MHC II expression in spinal microglia. ( 27742579 )	Song Z....Tian Y.	2017
33	Teniposide ameliorates bone cancer nociception in rats via the P2X7 receptor. ( 28825192 )	Yan J....Zeng Z.	2017
34	Effect of alkylaminophenols on growth inhibition and apoptosis of bone cancer cells. ( 28728976 )	Doan P....Kandhavelu M.	2017
35	Normalizing GDNF expression in the spinal cord alleviates cutaneous hyperalgesia but not ongoing pain in a rat model of bone cancer pain. ( 27716965 )	Ding Z....Song Z.	2017
36	Recombinant protein transduction domain-Cu/Zn superoxide dismutase alleviates bone cancer pain via peroxiredoxin 4 modulation and antioxidation. ( 28391978 )	Yao W....Liu J.	2017
37	The Molecular Genetic Expression as a Novel Biomarker in the Evaluation and Monitoring of Patients With Osteosarcoma-Subtype Bone Cancer Disease. ( 28425009 )	Hutanu D....Tanasescu S.	2017
38	Resveratrol attenuates bone cancer pain through regulating the expression levels of ASIC3 and activating cell autophagy. ( 29036449 )	Zhu H....Jiao M.	2017
39	Antinociceptive Effect of Intrathecal Injection of Genetically Engineered Human Bone Marrow Stem Cells Expressing the Human Proenkephalin Gene in a Rat Model of Bone Cancer Pain. ( 28286408 )	Sun Y....Sun Q.	2017
40	Bone cancer: Is the osteosarcoma genome targetable? ( 28776583 )	Savage S.A....Mirabello L.	2017
41	Efficacy and mechanism of action of etanercept in bone cancer pain. ( 29441991 )	Liao Y....Xu M.	2017
42	Bindarit Attenuates Pain and Cancer-Related Inflammation by Influencing Myeloid Cells in a Model of Bone Cancer. ( 29234825 )	Liu S....Xing D.	2017
43	Morin Suppresses Astrocyte Activation and Regulates Cytokine Release in Bone Cancer Pain Rat Models. ( 28618070 )	Jiang W....Zhang M.	2017
44	Hyperthermia effect and antibacterial efficacy of Fe(3+) /Co(2+) co-substitutions in I^-Ca3 (PO4 )2 for bone cancer and defect therapy. ( 28661574 )	Singh R.K....Kannan S.	2017
45	Plasma-induced selectivity in bone cancer cells death. ( 28571751 )	Canal C....Ginebra M.P.	2017
46	Multi-target treatment of bone cancer pain using synergistic combinations of pharmacological compounds in experimental animals. ( 28850433 )	Pertovaara A.	2017
47	The analgesic effects of triptolide in the bone cancer pain rats via inhibiting the upregulation of HDACs in spinal glial cells. ( 29096654 )	Hu X.F....Dong Y.L.	2017
48	Retraction Statement: CXCL12/CXCR4 chemokine signaling in spinal glia induces pain hypersensitivity through MAPKs-mediated neuroinflammation in bone cancer rats. ( 28417467 )		2017
49	Bufalin attenuates cancer-induced pain and bone destruction in a model of bone cancer. ( 28840279 )	Ji D....Fang J.	2017
50	Etanercept attenuates thermal and mechanical hyperalgesia induced by bone cancer. ( 28565880 )	Yang Y....Ma Z.	2017

Sources

Genes for Bone Cancer

Genes related to Bone Cancer (0 elite genes):

(show all 26)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	TRPV1	Transient Receptor Potential Cation Channel Subfamily V Member 1	Protein Coding	26.94	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
2	TNFSF11	TNF Superfamily Member 11	Protein Coding	21.56	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	MTAP	Methylthioadenosine Phosphorylase	Protein Coding	20.23	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	CYCS	Cytochrome C, Somatic	Protein Coding	20.08	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	TNFRSF11A	TNF Receptor Superfamily Member 11a	Protein Coding	20.03	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	P2RX7	Purinergic Receptor P2X 7	Protein Coding	19.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	IL6	Interleukin 6	Protein Coding	19.9	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	PDYN	Prodynorphin	Protein Coding	19.8	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	EWSR1	EWS RNA Binding Protein 1	Protein Coding	19.71	DISEASES inferred ¹⁵
10	ESR1	Estrogen Receptor 1	Protein Coding	19.49	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	MRC2	Mannose Receptor C Type 2	Protein Coding	19.48	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	CNR1	Cannabinoid Receptor 1	Protein Coding	19.44	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	MMP9	Matrix Metallopeptidase 9	Protein Coding	19.37	DISEASES inferred ¹⁵ ¹⁵
14	CCL2	C-C Motif Chemokine Ligand 2	Protein Coding	19.28	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	PENK	Proenkephalin	Protein Coding	19.23	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	BMI1	BMI1 Proto-Oncogene, Polycomb Ring Finger	Protein Coding	19.12	DISEASES inferred ¹⁵ ¹⁵
17	ATF3	Activating Transcription Factor 3	Protein Coding	19.05	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	COL1A1	Collagen Type I Alpha 1 Chain	Protein Coding	19	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	TRIM14	Tripartite Motif Containing 14	Protein Coding	10.3	DISEASES inferred ¹⁵ ¹⁵
20	RLN2	Relaxin 2	Protein Coding	9.75	DISEASES inferred ¹⁵ ¹⁵
21	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	8.6	DISEASES inferred ¹⁵ ¹⁵
22	TRAT1	T Cell Receptor Associated Transmembrane Adaptor 1	Protein Coding	8.03	DISEASES inferred ¹⁵ ¹⁵
23	ENG	Endoglin	Protein Coding	8.02	DISEASES inferred ¹⁵ ¹⁵
24	NOTCH1	Notch 1	Protein Coding	7.89	DISEASES inferred ¹⁵ ¹⁵
25	RECK	Reversion Inducing Cysteine Rich Protein With Kazal Motifs	Protein Coding	7.68	DISEASES inferred ¹⁵ ¹⁵
26	CD99	CD99 Molecule (Xg Blood Group)	Protein Coding	7.42	DISEASES inferred ¹⁵

Sources

Variations for Bone Cancer

Copy number variations for Bone Cancer from CNVD:

⁷

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	70082	12	58138784	58142025	Amplification	SAS	Bone cancer
2	70083	12	58141509	58146230	Amplification	CDK4	Bone cancer
3	71134	12	67700000	68661632	Amplification	MDM2	Bone cancer

Sources

Expression for Bone Cancer

Search GEO for disease gene expression data for Bone Cancer.

Sources

Pathways for Bone Cancer

Pathways related to Bone Cancer according to GeneCards Suite gene sharing:

(show all 15)

#	Super pathways	Score	Top Affiliating Genes
1	TNFR1 Pathway ⁶⁴ Show member pathways Apoptosis and survival TNFR1 signaling pathway ²² Apoptosis through Death Receptors ⁶⁴ Apoptotic Pathways Triggered By HIV1 ⁶⁴ DR3 Signaling ⁶⁴ Fas Signaling ⁶⁴ GITR Pathway ⁶⁴ HIV-1 Nef- Negative effector of Fas and TNF-alpha ¹ Stimulation of the cell death response by PAK-2p34 ⁶⁶ TNF alpha Signaling Pathway ¹ TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway ¹ TNF Signaling ⁶⁴ TRAIL Pathway ⁶⁴ TWEAK Pathway ⁶⁴	12.48	ATF3 CCL2 CYCS IL6 MMP9 TNFRSF11A
2	Development Endothelin-1/EDNRA signaling ²² Show member pathways Cytoskeleton remodeling FAK signaling ²² Development Endothelin-1/EDNRA transactivation of EGFR ²² GnRH signaling pathway ³⁷ Inflammatory mediator regulation of TRP channels ³⁷	12.39	COL1A1 CYCS TNFRSF11A TNFSF11 TRPV1
3	Transcriptional misregulation in cancer ³⁷	11.94	BMI1 EWSR1 IL6 MMP9
4	TNF signaling pathway ³⁷	11.77	CCL2 IL6 MMP9
5	Senescence and Autophagy in Cancer ¹	11.74	BMI1 COL1A1 IL6
6	AGE-RAGE signaling pathway in diabetic complications ³⁷	11.68	CCL2 COL1A1 IL6
7	Spinal Cord Injury ¹	11.64	CCL2 IL6 MMP9 PDYN
8	Microglia Activation During Neuroinflammation: Microglia Polarization ⁶⁵	11.48	CCL2 IL6 MMP9
9	Lung fibrosis ¹	11.41	CCL2 IL6 MMP9
10	Rheumatoid arthritis ³⁷	11.21	CCL2 IL6 TNFRSF11A TNFSF11
11	Validated transcriptional targets of AP1 family members Fra1 and Fra2 ¹	11.03	CCL2 IL6 MMP9
12	G-protein signaling_Rap2B regulation pathway ²²	10.78	CCL2 COL1A1 IL6 PENK TNFSF11
13	Osteoclast Signaling ¹	10.73	TNFRSF11A TNFSF11
14	Osteoblast Signaling ¹	10.64	COL1A1 TNFSF11
15	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²²	10.58	COL1A1 IL6 TNFRSF11A TNFSF11

Sources

GO Terms for Bone Cancer

Biological processes related to Bone Cancer according to GeneCards Suite gene sharing:

(show all 20)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	9.93	ATF3 IL6 P2RX7 RLN2 TNFSF11
2	positive regulation of apoptotic process	GO:0043065	9.89	CNR1 IL6 MMP9 P2RX7 TRPV1
3	cytokine-mediated signaling pathway	GO:0019221	9.87	CCL2 IL6 MMP9 TNFSF11
4	regulation of signaling receptor activity	GO:0010469	9.85	CCL2 IL6 PDYN PENK RLN2 TNFSF11
5	response to lipopolysaccharide	GO:0032496	9.83	CNR1 P2RX7 PENK TNFRSF11A
6	positive regulation of NF-kappaB transcription factor activity	GO:0051092	9.78	IL6 TNFRSF11A TNFSF11 TRIM14
7	response to bacterium	GO:0009617	9.77	CCL2 P2RX7 PENK
8	response to estradiol	GO:0032355	9.76	COL1A1 ESR1 PENK
9	osteoblast differentiation	GO:0001649	9.75	COL1A1 MRC2 PENK
10	ossification	GO:0001503	9.62	COL1A1 MMP9 TNFRSF11A TNFSF11
11	negative regulation of bone resorption	GO:0045779	9.56	IL6 P2RX7
12	PERK-mediated unfolded protein response	GO:0036499	9.55	ATF3 CCL2
13	tooth eruption	GO:0044691	9.51	COL1A1 TNFSF11
14	TNFSF11-mediated signaling pathway	GO:0071847	9.46	TNFRSF11A TNFSF11
15	sensory perception of pain	GO:0019233	9.46	CNR1 P2RX7 PENK TRPV1
16	positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling	GO:0071848	9.43	TNFRSF11A TNFSF11
17	mammary gland alveolus development	GO:0060749	9.43	ESR1 TNFRSF11A TNFSF11
18	positive regulation of fever generation by positive regulation of prostaglandin secretion	GO:0071812	9.4	TNFRSF11A TNFSF11
19	monocyte chemotaxis	GO:0002548	9.26	CCL2 IL6 TNFRSF11A TNFSF11
20	positive regulation of DNA-binding transcription factor activity	GO:0051091	9.02	ESR1 IL6 TNFRSF11A TNFSF11 TRIM14

Molecular functions related to Bone Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	opioid peptide activity	GO:0001515	8.62	PDYN PENK

Sources

Sources for Bone Cancer

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia

Bone Cancer

Aliases & Classifications for Bone Cancer

MalaCards integrated aliases for Bone Cancer:

Classifications:

External Ids:

Summaries for Bone Cancer

Related Diseases for Bone Cancer

Diseases in the Bone Cancer family:

Diseases related to Bone Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Bone Cancer:

Symptoms & Phenotypes for Bone Cancer

UMLS symptoms related to Bone Cancer:

MGI Mouse Phenotypes related to Bone Cancer:

Drugs & Therapeutics for Bone Cancer

FDA approved drugs:

Drugs for Bone Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 73 / NDF-RT 51 :

Cochrane evidence based reviews: bone neoplasms

Genetic Tests for Bone Cancer

Anatomical Context for Bone Cancer

MalaCards organs/tissues related to Bone Cancer:

Publications for Bone Cancer

Articles related to Bone Cancer:

Genes for Bone Cancer

Genes related to Bone Cancer (0 elite genes):

Variations for Bone Cancer

Copy number variations for Bone Cancer from CNVD:

Expression for Bone Cancer

Pathways for Bone Cancer

Pathways related to Bone Cancer according to GeneCards Suite gene sharing:

GO Terms for Bone Cancer

Biological processes related to Bone Cancer according to GeneCards Suite gene sharing:

Molecular functions related to Bone Cancer according to GeneCards Suite gene sharing:

Sources for Bone Cancer

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :